Market cap
$1 Mln
Revenue (TTM)
$37 Mln
P/E Ratio
--
P/B Ratio
54.9
Div. Yield
0 %
Quality Score
/10
Growth Score
/10
Valuation Score
/10
Momentum Score
/10
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$-111 Mln
-
ROE
-7.4 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
-2.2
-
Debt to Equity
-1.8
-
Book Value
$--
-
EPS
$--
-
Face value
--
-
Shares outstanding
3,531,710
10 Years Aggregate
CFO
$-559.11 Mln
EBITDA
$-512.31 Mln
Net Profit
$-716.98 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Quotient (QTNT)
| -89.5 | -46.1 | -94.9 | -99.9 | -94.5 | -82.0 | -- |
|
BSE Sensex*
| -10.4 | -1.0 | -7.8 | -7.7 | 6.7 | 8.3 | 11.1 |
|
Company
|
2022
|
2021
|
2020
|
2019
|
2018
|
2017
|
2016
|
|---|---|---|---|---|---|---|---|
|
Quotient (QTNT)
| -99.6 | -50.3 | -45.2 | 55.4 | 23.5 | 2.3 | -69.8 |
|
BSE Sensex
| 4.4 | 22.0 | 15.8 | 14.4 | 5.9 | 27.9 | 1.9 |
|
BSE Sensex
| 4.4 | 22.0 | 15.8 | 14.4 | 5.9 | 27.9 | 1.9 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Shareholding Pattern
View DetailsAbout Quotient (QTNT)
Quotient Limited, a commercial-stage diagnostics company, develops, manufactures, commercializes, and sells products for the global transfusion diagnostics market in the United States, France, Japan, and internationally. The company is developing... MosaiQ, a proprietary technology platform, which provides tests for immunohematology, serological disease screening, and molecular disease screening. Its conventional reagent products for blood grouping include antisera products that are used to identify blood group antigens; reagent red blood cells, which enable the identification of blood group antibodies; whole blood control products for use as daily quality assurance tests; and ancillary products that are used to support blood grouping. The company also offers MosaiQ SDS Microarray that is designed as a serological disease screening microarray comprised assays to detect cytomegalovirus and Syphilis; MosaiQ MDS Microarray that is designed as a molecular disease screening microarray test for donor red cells or source plasma; MosaiQ IH Microarray as a blood grouping microarray; MosaiQ Autoimmune Microarray; MosaiQ COVID-19; and MosaiQ IH3 Microarray. It sells its products to hospitals, donor collection agencies, independent testing laboratories, original equipment manufacturers, and blood banking operation and other diagnostics companies. Quotient Limited was founded in 2007 and is headquartered in Eysins, Switzerland. Read more
-
CEO & Director
Mr. Manuel O. Mendez
-
CEO & Director
Mr. Manuel O. Mendez
-
Headquarters
Eysins
-
Website
FAQs for Quotient (QTNT)
What is the current share price of Quotient Ltd (QTNT) Today?
The share price of Quotient Ltd (QTNT) is $0.04 (NASDAQ) as of 03-Mar-2023 09:30 EDT. Quotient Ltd (QTNT) has given a return of -94.51% in the last 3 years.
What is the current PB & PE ratio of Quotient Ltd (QTNT)?
Since, TTM earnings of Quotient Ltd (QTNT) is negative, P/E ratio is not available.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2022
|
--
|
--
|
|
2021
|
--
|
--
|
|
2020
|
--
|
--
|
|
2019
|
--
|
--
|
|
2018
|
--
|
--
|
What is the 52 Week High and Low of Quotient Ltd (QTNT)?
The 52-week high and low of Quotient Ltd (QTNT) are Rs -- and Rs -- as of 28-May-2026.
What is the market cap of Quotient Ltd (QTNT)?
Quotient Ltd (QTNT) has a market capitalisation of $ 1 Mln as on 03-Mar-2023. As per SEBI classification, it is a company.
Should I invest in Quotient Ltd (QTNT)?
Before investing in Quotient Ltd (QTNT), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.